Nachrichten zur Cellectis S.A. Aktie

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis…

Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript

…

Cellectis S.A.: Barclays sieht nach einem starken Quartalsbericht weiterhin 125 % Kurspotenzial!

Cellectis S.A. (CLLS) ist ein klinisch tätiges Biotechnologieunternehmen, das seine führende Gen-Editierungs-Plattform nutzt, um lebensrettende Zell- und Gentherapien zu entwickeln.…

[Latest] Global Genetic Engineering Market Size/Share Worth USD 2,917.2 Million by 2033 at a 6.74% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Global Genome Editing Market Size To Worth USD 34.75 Billion By 2033 | CAGR Of 16.19%

The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market…

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

…